Table 2.
Recurrence-free survival (RFS) for 48 patients enrolled on study
| Variable | N | Median (mo) | 1-year RFS | 2-year RFS | 5-year RFS | HR | 95% CI | P |
|---|---|---|---|---|---|---|---|---|
| All subjects | 48 | 15.62 (13.35, 17.88) | 65 (53, 81) | 31 (19, 49) | 16 (7, 39) | |||
| Age <65 | 32 | 17.03 (11.51, 72.8+) | 65 (50, 84) | 33 (19, 58) | 17 (5, 51) | 1 | - | |
| Age 65+ | 16 | 15.35 (9.3, 72.8+) | 66 (46, 95) | 25 (9, 65) | 16 (5, 58) | 1.17 | (0.56, 2.44) | .67 |
| Tumor diameter ≤3 cm | 23 | 17.88 (16.31, 72.8+) | 74 (58, 94) | 50 (31, 79) | 21 (7, 65) | 1 | - | |
| Tumor diameter >3 cm | 25 | 13.97 (9.3, 17.49) | 57 (40, 81) | 14 (5, 41) | 14 (5, 41) | 2.03 | (0.99, 4.16) | .05 |
| Isolated recurrence pattern | 27 | 11.51 (8.35, 15.62) | 48 (33, 71) | 11 (4, 32) | 0 (NA, NA) | 1 | - | |
| Synchronous recurrence pattern | 4 | 12.92 (4.08, 36.4+) | 50 (19, 100) | 0 (NA, NA) | 0 (NA, NA) | 0.97 | (0.33, 2.83) | .96 |
| Negative margin status | 40 | 15.62 (13.97, 72.8+) | 68 (55, 85) | 35 (22, 57) | 23 (10, 50) | 1 | - | |
| Positive margin status | 8 | 11.88 (8.35, 72.8+) | 50 (25, 100) | 12 (2, 78) | 0 (NA, NA) | 1.88 | (0.84, 4.22) | .13 |
| Male | 20 | 15.62 (13.97, 72.8+) | 74 (56, 96) | 29 (13, 64) | 11 (2, 58) | 1 | - | |
| Female | 28 | 16.31 (8.45, 72.8+) | 60 (44, 81) | 32 (17, 58) | 21 (8, 58) | 0.97 | (0.48, 1.97) | .94 |
| Uninvolved lymph nodes | 7 | 17.88 (13.97, 72.8+) | 86 (63, 100) | 36 (12, 100) | 0 (NA, NA) | 1 | - | |
| Involved lymph nodes | 41 | 15.35 (11.51, 27.39) | 61 (48, 79) | 30 (18, 51) | 19 (8, 44) | 1.28 | (0.49, 3.34) | .61 |
| Grade <3 | 32 | 17.03 (13.97, 72.8+) | 74 (60, 91) | 32 (18, 57) | 0 (NA, NA) | 1 | - | |
| Grade 3+ | 16 | 13.38 (9.3, 72.8+) | 50 (31, 82) | 29 (13, 64) | 21 (8, 57) | 1.05 | (0.51, 2.18) | .9 |
| Tumor in body/tail | 10 | 13.35 (8.45, 72.8+) | 56 (31, 100) | 22 (7, 75) | 0 (NA, NA) | 1 | - | |
| Tumor in head | 38 | 17.03 (13.97, 33.57) | 68 (54, 85) | 33 (19, 55) | 20 (9, 48) | 0.69 | (0.31, 1.55) | .37 |
| ECOG 0 | 34 | 15.48 (11.51, 27.39) | 63 (48, 82) | 26 (14, 51) | 9 (2, 49) | 1 | - | |
| ECOG 1 | 14 | 17.03 (12.26, 72.8+) | 71 (50, 100) | 39 (20, 77) | 26 (9, 75) | 0.71 | (0.32, 1.55) | .39 |
| Baseline CA19-9 above median | 23 | 15.48 (11.51, 72.8+) | 66 (49, 90) | 15 (4, 51) | 0 (NA, NA) | 1 | - | |
| Baseline CA19-9 below median | 23 | 17.88 (13.35, 72.8+) | 70 (53, 91) | 45 (28, 72) | 29 (13, 64) | 0.57 | (0.27, 1.21) | .14 |
| No dermatitis | 14 | 9.3 (5.95, 72.8+) | 45 (24, 83) | 22 (7, 71) | 0 (NA, NA) | 1 | - | |
| Dermatitis | 34 | 16.31 (15.25, 72.8+) | 73 (59, 90) | 34 (20, 57) | 25 (12, 54) | 0.43 | (0.21, 0.9) | .02 |
Abbreviations CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio.
Median RFS is shown in months with a 95% CI. Values for RFS probability at 1, 2, and 5 years are shown with 95% CIs. All HRs and P values are derived from univariate models.